AXSM · Axsome Therapeutics, Inc.
$241.53
+1.91 (+0.80%)
At close · Jul 23
Market Cap
$12.43B
Shares
51.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$638.5M
+65.5%
FY2025
Net Income
-$183.17M
+36.2%
FY2025
Operating Margin
-26.12%
+46.6pp
FY2025
Diluted EPS
-$3.68
+38.6%
FY2025
Operating Cash Flow
-$93.41M
+27.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $708.24M | $638.5M | $385.69M | $270.6M | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | $5.2M | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$5.2M | — | — | — | — | — | — | — | — | |
| $191.17M | $183.28M | $187.08M | $97.94M | $57.95M | $58.06M | $70.24M | $53.65M | $23.5M | $19.96M | $21.2M | $6.78M | $4.28M | |
| $494.55M | $440.4M | $293.36M | $237.23M | $104.66M | — | — | — | — | — | — | — | — | |
| $73.65M | $63.27M | $54.2M | $37.36M | $25.47M | $66.65M | $28.9M | $13.6M | $9.35M | $7.21M | $6.34M | $2.42M | $1.39M | |
| $634.81M | $570.6M | $411.36M | $323.12M | $159.25M | $66.65M | $28.9M | — | — | — | — | — | — | |
| $6.38M | $6.38M | $6.39M | $6.38M | $4.14M | — | — | — | — | — | — | — | — | |
| $135.15M | — | — | — | — | $124.71M | $99.14M | $67.25M | $32.85M | $27.16M | $27.54M | $9.2M | $5.67M | |
| $881.37M | $805.26M | $666.26M | $502.43M | $229.84M | $124.71M | $99.14M | — | — | — | — | — | — | |
| -$173.14M | -$166.76M | -$280.56M | -$231.83M | -$179.8M | -$124.71M | -$99.14M | -$67.25M | -$32.85M | -$27.16M | -$27.54M | -$9.2M | -$5.67M | |
| — | -26.12% | -72.74% | -85.67% | — | — | — | — | — | — | — | — | — | |
| -$18.09M | -$15.93M | -$21.58M | -$20.03M | -$9.66M | — | — | — | — | — | — | — | — | |
| -$188.83M | -$183.7M | -$287.13M | -$238.28M | -$187.13M | -$130.4M | — | — | — | — | — | — | — | |
| -$530K | -$530K | $85K | $960K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| -$188.3M | -$183.17M | -$287.22M | -$239.24M | -$187.13M | -$130.4M | -$102.9M | -$68.35M | -$30.97M | -$28.94M | -$27.2M | -$12.21M | -$6M | |
| — | -28.69% | -74.47% | -88.41% | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$3.68 | -$5.99 | -$5.27 | -$4.60 | -$3.47 | -$2.77 | — | — | — | — | — | — |
| USD/shares | — | -$3.68 | -$5.99 | -$5.27 | -$4.60 | -$3.47 | -$2.77 | — | — | — | — | — | — |
| shares | — | 49.75M | 47.91M | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M | 11.95M | 9.1M |
| shares | — | 49.75M | 47.91M | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M | 11.95M | 9.1M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
17.38×
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.02×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $628,617,000 | $378,159,000 | $197,224,000 | — |
| Non Us | $9,879,000 | $7,534,000 | $75,781,000 | $900,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Product | $633,796,000 | $381,677,000 | $202,460,000 | $50,037,000 |
| Royalty and Milestone Revenue | $4,700,000 | $4,016,000 | $2,405,000 | — |
| License | — | — | $65,735,000 | — |
Key facts
CIK
1579428
CUSIP
05464T104
13F (30d)
64 filings
63 filers
Visit website
Investor relations